{
    "clinical_study": {
        "@rank": "72031", 
        "acronym": "CERBERUS", 
        "biospec_descr": {
            "textblock": "Microbiological strains"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "Approximately 3,000 of clinically significant isolates of different species from respective\n      respective sources  in geographically distinct Russian cities will be collected and tested\n      on ceftaroline and other antimicrobials."
        }, 
        "brief_title": "Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Bacterial Skin Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Skin Diseases", 
                "Skin Diseases, Bacterial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Isolates derived from patients' clinical material will be included in the study\n\n          -  Isolates collected retro- and prospectively will be included in the study (from\n             01.01.2008 till 31.12.2012)\n\n          -  Isolates, allocated of a clinical material of adult patients (> 18 years), should\n             make not less than 70 % from total number of included isolates)\n\n          -  All included isolates should be unique:  only one isolate can be included in the\n             study of each biological type from each patient\n\n          -  All isolates should correspond to clinic-laboratory criteria of the etiologic\n             importance, i.e. should be derived from patients with infection symptoms from the\n             corresponding clinical material\n\n          -  Case report form (CRF) (Appendix 1) should be correctly completed for each isolate\n\n        Exclusion Criteria:\n\n          -  ESBL-producing representatives of Enterobacteriaceae (ESBL-Extended-spectrum\n             beta-lactamase)\n\n          -  Isolates, arrived in the central laboratory contaminated or unviable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "clinical material form patients in geographically distinct Russian cities"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700842", 
            "org_study_id": "NIS-IRU-XXX-2012/1"
        }, 
        "intervention_browse": {
            "mesh_term": "Anti-Infective Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ceftaroline, infection, CAPB, CAP, ABSSSI, cSSTI", 
        "lastchanged_date": "June 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: SUBMISSION NOT  REQUIRED"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "MIC- Minimum inhibitory concentration; EUCAST - European Committee on Antimicrobial Susceptibility Testing; CLSI-  Clinical and Laboratory Standard Institute", 
            "measure": "Percentage(numerical) MIC distribution of microorganisms for ceftaroline and other tested antimicrobials, including MIC50 and MIC90, percent(quantity)of susceptible and resistant strains in accordance with EUCAST or CLSI recommended breakpoints.", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage(numerical)MIC distribution of microorganisms,including MIC50 and MIC90, percent(quantity) of susceptible and resistant strains, to tested antibiotics depend on: infection localization, medical condition, ward/unit profile,patient profile(age)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months"
            }, 
            {
                "measure": "Percentage(numerical)MIC distribution of microorganisms,including MIC50 and MIC90, percent(quantity) of susceptible and resistant strains,to ceftaroline and other antimicrobials by years from 2008 to 2012", 
                "safety_issue": "No", 
                "time_frame": "upto 3 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}